A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Inclusion Criteria:

1. Voluntarily provide signed informed consent after review of verbal and writtenmaterial about the trial and agree to abide with protocol requirements. All studyrelated activities must be carried out after written consent is obtained.

2. Subjects must be ≥18 years of age at the time of signing the ICF (Informed ConsentForm).

3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) status of 0 - 2.

4. For MM, subjects must have measurable disease by IMWG (International Myeloma WorkingGroup) 2016 criteria

5. For DLBCL, subjects must have measurable disease by Lugano criteria

6. Females must not be breastfeeding or pregnant at screening

7. Females of childbearing potential must not have had unprotected sexual intercoursewhile participating in this study

8. Male subjects must either practice complete abstinence or agree to use a latex orsynthetic condom, even with a successful vasectomy, during study treatment and for 30 days after the final dose of study treatment

Exclusion Criteria:

1. Subjects with plasma cell leukemia defined as a plasma cell count >2000/mm3.

2. Subjects with Waldenstrom's macroglobulinemia or smoldering MM.

3. Subjects who had prior treatment with SETD2 or NSD2 inhibitor.

4. Subjects with active acute or chronic systemic infection requiring systemictreatment, including COVID-19.

5. Has cardiovascular impairment

6. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 480msec or history of long QT syndrome.

7. Known left ventricular ejection fraction (LVEF) < 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA).

8. Prior major surgery within 4 weeks of treatment start.

9. Known hypersensitivity to components of the investigational product.

10. Subjects who have received treatment with any unapproved drug product within 4 weeksprior to screening.

11. Current participation in any other interventional clinical study except for followup.

12. Subjects with a history of or active malignancy other than disease under study

13. Underlying medical/social conditions that in PI opinion will place the subject insignificant risk and affect the interpretation of toxicity and adverse eventsassessments.

14. Inability to take oral medication or known gastrointestinal (GI) disease, GIprocedure or medical condition that could interfere with the oral absorption ortolerance of the study drug